Farewell Pharma Friends! Beware of the PharmaGovernment Complex!
It's my 71st birthday and I decided it's a good time for me to move on to a new role. Unbelievable, right? John " PharmaGuy " Mack is seventy-one years old!Also unbelievable is that I am shuttering my pharmaceutical online publishing business after 16 years of continuous operation! There will be no more Pharma Industry News Update emails, no more PharmaGuy Insights on Scoop.it, and no new Pharma Marketing Blog posts. There will still be  tweets from @pharmaguy, but eventually even that will end.Although one door has closed, another door has opened for me as a Newtown Township, PA Supervisor. Yes, I am now a ...
Source: Pharma Marketing Blog - February 6, 2018 Category: Pharmaceuticals Source Type: blogs

Why Has There Been a Drop in FDA Enforcement Activity?
That's one question on the mind of EyeOnFDA author Mark Senak of FleishmanHillard's Washington, D.C. office. Senak plotted the number of"Action Letters," which are Warning Letters to drug company CEOs plus so-called"untitled" letters addressed to underlings - usually regulatory officers. I copies his chart - find the originalhere - and highlighted the years in which a Democrat (D; blue) or Republican (R; red) was in the White House.The FDA's Chief Counsel between August 2001, and November, 2004 was Bush-appointed Daniel E. Troy. Soon after being appointed, Troy instituted a legal review of r...
Source: Pharma Marketing Blog - November 1, 2017 Category: Pharmaceuticals Tags: FDA untitled letters warning letters Source Type: blogs

Dancing with Fentanyl: Insys Sales Reps Caught Rapping to Boost Sales
You can't make this stuff up!According toHuffington Post, " Pharmaceutical sales representatives selling an opioid-based drug 50 times more powerful than heroin filmed a company-made rap video in which they danced with a giant bottle of their deadly fentanyl spray, a federal grand jury alleged in an indictment unsealed this week (for more about that, read "Founder of Insys Indicted for Bribing Docs to Illegally Prescribe Fentanyl. Lock Him Up!" )." The grand jury alleged that'prominent'sales reps at Insys Therapeutics Inc. appeared in a 2015 music video that used a song by rapper A$AP Rocky, which was p...
Source: Pharma Marketing Blog - October 28, 2017 Category: Pharmaceuticals Tags: Fentanyl Insys Opioids Sales and Sales Reps Source Type: blogs

Purdue's Opioid Marketing is Target of a Federal Criminal Probe
As reported by Bloomberg:Federal prosecutors in Connecticut began a criminal investigation into Purdue Pharma Inc. ’s marketing of the controversial opioid painkiller OxyContin.U.S. Attorney Deirdre Daly is gathering documents about Purdue ’s claim that OxyContin provides 12 hours of pain relief. A Los Angeles Times investigation, published last year, found that Purdue ignored evidence showing the drug’s effects failed to last that long in some patients, increasing the risk of withdrawal, abuse and addiction. “Purdue is committed to being part of the solution to our nation’s opioid c...
Source: Pharma Marketing Blog - October 26, 2017 Category: Pharmaceuticals Tags: Opioids Purdue Pharma Source Type: blogs

Is The End of Animated Characters in Drug Ads Neigh?
Merck has decided to dump its furry white vs black feline critters in its new direct-to-consumer advertising campaign for Belsomra saying that “the original ad served its purpose " ; namely, breaking through the TV drug ad clutter to be noticed. Read the story below.I have to ask if this is a trend now that each brand using mascots has already " broken through " AND the FDA is beginning to look more closely at the use of animated characters in ads (read "FDA Will Apply the'Uncanny Valley'Hypothesis to Test the'Eeriness'of Animated Characters in Drug Ads" ). Or is it just Merck who got the jit...
Source: Pharma Marketing Blog - October 9, 2017 Category: Pharmaceuticals Tags: Belsomra FDA Mascots Merck Sleep Aid Drugs Source Type: blogs

Is The End of Animated Characters in Drug Ads Neigh!
Merck has decided to dump its furry white vs black feline critters in its new direct-to-consumer advertising campaign for Belsomra saying that “the original ad served its purpose " ; namely, breaking through the TV drug ad clutter to be noticed. Read the story below.I have to ask if this is a trend now that each brand using mascots has already " broken through " AND the FDA is beginning to look more closely at the use of animated characters in ads (read "FDA Will Apply the'Uncanny Valley'Hypothesis to Test the'Eeriness'of Animated Characters in Drug Ads" ). Or is it just Merck who got the jit...
Source: Pharma Marketing Blog - October 9, 2017 Category: Pharmaceuticals Tags: Belsomra FDA Mascots Merck Sleep Aid Drugs Source Type: blogs

Does This Email Message from KVK Tech Violate FDA Regulations?
Today, I received an email message from KVK Tech - a generic drug manufacturer located in my my hometown of Newtown, PA - regarding a gift to Stanford's Department of Bariatric and Minimally Invasive Surgery (see below; ignore that the email has the wrong date on it - you can't expect a drug company to have good copy editors, can you?). It talks about obesity in the U.S.At the end of the email, in the " About KVK Tech " section, it mentions that it manufactures and distributes Lomaira, which is a drug to treat obesity. Unfortunately, KVK Tech does not mention the Important Safety Information (ISI) whenever a drug...
Source: Pharma Marketing Blog - September 28, 2017 Category: Pharmaceuticals Tags: FDA KVK Tech Obesity drugs regulations Source Type: blogs

Is FDA Most Science-Based and Less patient Centric Now that Gottlieb is in Charge?
Last October, FDA caved in to patients lobbying on behalf of Sarepta's Duchenne drug Exondys 51 despite the fact that there was little scientific evidence that it was effective (read "FDA Succumbs to Industry-Sponsored Patient Power& Accelerates Approval of Sarepta's Duchenne Drug" ).Now, another company -- PTC Therapeutics -- is seeking approval for a competing drug and the FDA warned in a briefing document that it the company should not depend on the same tactics to get its drug approved. Will paid patient lobbyists sway FDA just like they did for Sarepta? Or is the FDA now more science-based that Gott...
Source: Pharma Marketing Blog - September 27, 2017 Category: Pharmaceuticals Tags: Duchenne FDA Source Type: blogs

Specialty Brand Sales Excel Today, But What About Tomorrow?
@QuintilesIMS teamed up with #PharmaForce to provide a framework for product launch assessment. The following is an excerpt. Download the entire reporthere.The chart below shows the total amount of revenue associated with launch brands in the year that they launch. " From 2000-2006, " notes QuintilesIMS, " we see that somewhere between $3 billion and $5 billion were spent on launch brands in the first 12 months in which they were launched. These are your traditional, big primary care type of products. "Further quoting from the report:" The launch figures dropped down in 2007-2010, and this is where...
Source: Pharma Marketing Blog - August 25, 2017 Category: Pharmaceuticals Tags: Launch specialty drugs Source Type: blogs

PhRMA May Be Shooting Itself in the Foot by Criticizing FDA DTC Studies
As reported by RAPS (here), the Pharmaceutical Research and Manufacturers of America (PhRMA) is"harshly criticizing the US Food and Drug Administration's (FDA) research focused on prescription drug advertising and promotion and calling for a clearer vision on how this research protects public health.""FDA has proposed to undertake projects in a variety of disparate topics without articulating a clear, overarching research agenda or adequate rationales on how the proposed research related to the goal of further protecting public health. Within the last year, the Agency has increased such efforts at an exp...
Source: Pharma Marketing Blog - August 17, 2017 Category: Pharmaceuticals Tags: DTC Advertising FDA PhRMA Study Source Type: blogs

" Fake Advertising " : Allergan Should Be Red in the Face for Using " Before & After " Images in Rhofade & Kybella Ads
Allergan is again resorting to side-by-side"before and after ” images in a drug ad to prove that Rhofade - its new drug for the treatment of redness of the face, aka rosacea - works. This is the same technique the company used  to promote Kybella for double chin syndrome.In the Kybella case, I analyzed the figures and suspected foul play; i.e., the after image was just a retouched version of the before image. That ad, however, claimed they were “unretouched photos” (read"Kybella Double Chin TV Ad: Are the BEFORE& AFTER Photos REALLY Unretouched as Claimed?").Despite some anonymous ...
Source: Pharma Marketing Blog - August 8, 2017 Category: Pharmaceuticals Tags: Allergan Fake Advertising Kybella Rhofade rosacea Source Type: blogs

Is FDA Too Slow to Approve New Drugs?
Back in March, 2017, President Trump"called on the Food and Drug Administration to speed the approval of drugs to treat life-threatening diseases, deriding the agency ’s current process as'slow and burdensome' ”(here).According to Dr. Michael Carome, Director, Public Citizen ’s Health Research Group, president Trump’s claims that the U.S. Food and Drug Administration’s approval process for medical products is “slow and burdensome” and “keeps too many advances … from reaching those in need,” reflect complete ignorance about the FDA’s current reg...
Source: Pharma Marketing Blog - July 5, 2017 Category: Pharmaceuticals Tags: Drug Approval FDA Pence Right to Try Source Type: blogs

The Forgotten eHealth Code of Ethics
Recently, I was sorry to see that theeHealth Code of Ethics, which I helped create back in 2000, was not included in the list of references to an article about trust and credibility of web-based health information. According to the Code, individuals need to be able to judge for themselves the quality of the health information they find on the Internet. Sites should disclose what sources the site or content provider has used, with references or links to those sources.Any research or effort designed to improve the quality of health information on the Internet must build upon the work already done by the creators of the inter...
Source: Pharma Marketing Blog - June 27, 2017 Category: Pharmaceuticals Tags: eHealth Ethics Source Type: blogs

Some PhRMA Board Member Opioid-Producing Companies are NOT Signatories to Its DTC Advertising Principles & Code on Interactions with Healthcare Professionals. Why Not?
In December 2008, the PhRMA Board of Directors unanimously adopted measures to enhance thePhRMA Guiding Principles on Direct to Consumer Advertisements about PrescriptionMedicines. The revised Principles took effect March 2, 2009.Despite the thundering unanimity of the PhRMA Board, several current board members are NOTsignatories to the principles. Specifically, Allergan, Alexion, Alkermes, Teva, and UCB are not signatories even though the CEOs of these companies are current PhRMA board members!Most disturbing to me is that opioid manufacturers and marketers Allergan, UCB, and Alkermes have not agreed to obey the DTC guide...
Source: Pharma Marketing Blog - June 12, 2017 Category: Pharmaceuticals Tags: Alkermes DTC Advertising Opioids PhRMA PhRMA Guidelines Physician Marketing Source Type: blogs

Funny, Witty, Snarky Pharmaguy Memes About Pharma
The original, pre-internet definition of a meme is, “an element of a culture on system of behavior that may be considered to be passed from one individual to another by non-genetic means, especially imitation”.Today, the “element of culture” is often an image or photo that has spread through social media or texting and which has been modified to include overlaid text. At least, that is how my son defines meme.Over the years I have created numerous memes that I hope will be copied and passed on from one pharmaceutical marketer to another. This PowerPoint presentation includes many of my favorite meme...
Source: Pharma Marketing Blog - June 5, 2017 Category: Pharmaceuticals Tags: Meme snarky Source Type: blogs

Defining " Patient Centricity "
Patient Centricity used to be a buzzword in that it was often mentioned but seldom practiced by pharma companies.A lot of progress has been made in the past years to achieve patient centricity, but not all drug companies have had much success. Unfortunately, that has had a negative impact on the industry ’s reputation.Timothy White, Head of Global Customer Interaction Management at Lundbeck, once said people on the commercial side of the pharma business have an “unhealthy obsession with ‘buzzwords’.”Worse than that, noted White, marketers cannot articulate the usefulness of the buzzwords they ...
Source: Pharma Marketing Blog - June 2, 2017 Category: Pharmaceuticals Tags: Drug prices Lobbying patient centricity Reputation Source Type: blogs

Pharma's Reputation Depends on Who You Ask
Depending on who you ask, the drug industry's reputation is at an all-time low (read, for example,"Pharma ’s Rep Among Patient Groups Sinks to Near Historical Lows") or an all-time high!For example, if you determine the reputation of a pharma company measured by"the general public who are somewhat or very familiar with the company," then that company's reputation is likely to score much higher than if you asked the general public whose"familiarity" with the company is not a factor.According to Reputation Institute's annual Global Pharma RepTrak ®, which uses the former pr...
Source: Pharma Marketing Blog - June 1, 2017 Category: Pharmaceuticals Tags: Reputation Source Type: blogs

FDA Has Many Hurdles to Overcome in its Effort to Stem the Current Opioid Addiction Epidemic it Helped to Create
The FDA has made many efforts to deal with the current opioid addiction crisis. The latest is the establishment of a"Opioid Policy Steering Committee." Some of these efforts may have been compromised by the influence of patient advocacy groups sponsored by drug companies that produce and market opioids. Such groups have gotten a seat on FDA panels. So, one has to wonder who will be named to the new steering committee.Listen to podcast below:Read the transcript, which includes links to more information, below.Read more » (Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - May 27, 2017 Category: Pharmaceuticals Source Type: blogs

PhRMA Gets Religion & Purges Low Hanging Fruit
PhRMA, the pharmaceutical industry's primary lobbying group, announced changes to its membership structure that purged 22 companies of their membership or associate membership status.Now, to be a member of PhRMA, you have to spend at least $200 million per year spent on research and research expenditures must equal to at least 10% of global sales (click on"Read more>>" below for details).Back in January, John LaMattina (@John_LaMattina) former president of Pfizer Global R&ampD, writing in Forbes, suggested that big pharma companies secede from PhRMA."I cannot help but wonder if the interests of...
Source: Pharma Marketing Blog - May 10, 2017 Category: Pharmaceuticals Tags: Drug prices Pfizer PhRMA Source Type: blogs

The Benefits and Risks of Limiting Pharma Sales Rep Access to Physicians
Pharmaceutical sales representatives are faced with increasingly limited access to physicians as many academic medical centers and other healthcare centers adopt conflict of interest policies restricting detailing. This is another benefit versus risk challenge for physicians who need quick access to the latest information about novel drugs. Listen to podcast below:Read the transcript, which includes charts, below.Read more » (Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - May 5, 2017 Category: Pharmaceuticals Tags: detailing Sales and Sales Reps Sales Force Effectiveness Source Type: blogs

March for Science, Why I March
Live from Washington, D.C.I will be heading to a satellite march in Doylestown, PA and speaking there. Here's what I will say:My name is John Mack and I live in Newtown.On Twitter I am known as PharmaGuy – that’s P-H-A-R-M-A, plus “Guy!” I PUBLISH a newsletter for the pharmaceutical industry. And I have a graduate degree in Biochemistry.Every day we benefit from medicines andvaccines created by scientists who work in pharmaceutical and government-funded research laboratories.We need to discover new drugs faster and defend efforts that make those drugs cheaper and more accessible to everyone.In ...
Source: Pharma Marketing Blog - April 22, 2017 Category: Pharmaceuticals Tags: March for Science Source Type: blogs

Speedy Drug Approval Versus Safe Drugs: Can We Have Both?
More user fees paid to the FDA by the drug industry and the push for less rigorous scientific proof in clinical trials may lead to faster drug approvals, but also more deaths due to side effects. Where ’s the balance between speed and safety?For the last few years I have been tracking data from the FDA regarding how much money it collects from the drug industry in prescription drug user fees to see those payments influence more than just how quickly the FDA is able to approve new drugs for marketing.One stark correlation I noted with the rise in user fees was the sharp drop in the number of warning letters the FDA se...
Source: Pharma Marketing Blog - April 19, 2017 Category: Pharmaceuticals Tags: Adverse events Drug Safety FDA PDUFA Source Type: blogs

Making Sense of DTC Ad Spending
About this time every year, I get data from Kantar Media and Nielsen regarding how much money the U.S. pharmaceutical industry spends on direct-to-consumer (DTC) advertising.The data I ’m most interested in are the total spend for the year and what portion of that is digital versus TV. But it can be difficult to ferret out that information from the two different sources, which often report different numbers.Let ’s look at the total spend first.According to Nielsen numbers reported in the March 3 2017 issue of MM&M online, spending on direct-to-consumer pharmaceutical ads rose 9% to $5.6 billion in 2016 (rea...
Source: Pharma Marketing Blog - April 5, 2017 Category: Pharmaceuticals Tags: Ad Spend DTC Advertising Source Type: blogs

A Drug By Any Other Name
The naming of drugs has been described both as a science and an art, which is also true about marketing in general.No matter what side of the brain is involved, there must be a reason why drug names are often ridiculed as being"absurd." The issue even made it to Saturday Night Live skit in which Oscar nominee Octavia Spencer sued Merck for naming dozens of drugs after members of her family ("Pharma Gets Drug Names from Octavia Spencer ’s Phone Contact List").Perhaps my reporting of that skit was the reason why my long-time friend, Jonathan Richman, founder and director of Dose Marketing in Cincinn...
Source: Pharma Marketing Blog - April 3, 2017 Category: Pharmaceuticals Tags: Adherence Brand drug name Source Type: blogs

PharmaGuy To Compete for Recognition at Cannes Lion Health Festival
April 1, 2017: PharmaGuy is excited to announce that the organizers of the 2017 Cannes Lion Health Festival have chosen him as one of the finalists to compete for this year ’sOld Pharma Lions Award!Judges are seeking out the greatest generation of older, awe-inspiring pharma marketing communications pundits. This year ’s competitors will put their snarkiness to the test on a brief set by UNIPHARM, the world’s leading organization working to revive the reputation of the endangered pharmaceutical industry (for more on that, read"Pharma Industry Reputation Hits 7-Year Low According to Harris Poll")...
Source: Pharma Marketing Blog - April 1, 2017 Category: Pharmaceuticals Tags: #LionsHealth Awards Source Type: blogs

Which is Bigger: Pharma Profits or R & D Spending?
On Mar 27, 2017, Public Citizen came out with a report that claimed"Pharmaceutical Industry Profits Are Nearly Double R&D Costs in 2013, 2014 and 2015". The email announcing the report said “Even the inflated estimates of R&D reported by the industry are dwarfed by the industry ’s profits, which, for the 20 largest pharmaceutical companies, jumped from $100.5 billion in 2014 to $123 billion in 2015.”“Big Pharma says that high prices pay for R&D, but it turns out they pay almost twice as much for sky-high corporate profits, ” said Robert Weissman, president of Public Citiz...
Source: Pharma Marketing Blog - March 28, 2017 Category: Pharmaceuticals Tags: Profits Public Citizen & D Source Type: blogs

The Context Problem Foils Pharma Online Advertising
Click on image to enlarge.Last week I came across an article about Johnson& Johnson and other pharma companies pulling their ads from Youtube because they appeared adjacent to hate speech, e.g.; an anti-Semitic clip claiming the existence of a “Jewish World Order” (see the back story embedded at the end of this post orclick here).In an official statement Johnson& Johnson said it paused all YouTube digital advertising globally “to ensure our product advertising does not appear on channels that promote offensive content. We take this matter very seriously and will continue to take every measure to e...
Source: Pharma Marketing Blog - March 27, 2017 Category: Pharmaceuticals Tags: Digital Janssen Programmatic Advertising YouTube Source Type: blogs

How Many Adverse Event Reports Are Submitted to the FDA? Whatever the Answer, It's at an All-Time High!
I've been tracking the number of adverse event reports (AERs) submitted to the FDA over the years based on data supplied by the FDAhere. The latest update of that data was made in November 2015 showing the number of AERs FDA received in the first quarter (Q1) of 2015.If you assume that the submission rate seen in Q1 of 2015 remained constant throughout the year, you get the following trend chart based on FDA's summary data table:Click on image for enlarged view.According this analysis, about 2.25 million AERs were submitted by healthcare professionals (HCPs) and consumers in 2015. An analysis by theMilwaukee Journa...
Source: Pharma Marketing Blog - March 20, 2017 Category: Pharmaceuticals Tags: Adverse events Drug Safety FDA side effects Source Type: blogs

Gottlieb to Head FDA: Pharma Breathes a Sigh of Relief
Trump Chooses Scott Gottlieb to Head FDA; Pharma Breathes Sigh of Relief (Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 13, 2017 Category: Pharmaceuticals Tags: FDA Gottlieb Source Type: blogs

DTC Advertising in the Era of High Drug Prices
TV and, to a lesser extent, print direct-to-consumer (DTC) drug ads have often been blamed for the high price of drugs. For example:Physician and pharmacist organizations say DTC ads are a waste of resources, which could be better used to lower drug prices or be plowed back into research (read, for example,"Pharmacists Say DTC Advertising Must Go: It's'Not Working'& Wastes Resources").  Some lawmakers claim that advertising inflates health care costs because consumers are prompted to seek newer, higher-priced medicines (read, for example,"DTC Advertising Moratorium Idea Resurrected in Co...
Source: Pharma Marketing Blog - March 13, 2017 Category: Pharmaceuticals Tags: Drug prices DTC Advertising Ehrlich Source Type: blogs

How to Make WebMD Great Again!
World of DTC Marketing blog author and pharma marketing consultant Richard Meyer has some advice forWebMD, which may be looking for a buyer (read “’Same Amount of Eggs, More Baskets’ – Lesson Learned by WebMD re Pharma Digital Spending”).“WebMD needs pharma and medical device companies, but pharma doesn ’t needWebMD, ” says Meyer who has some suggestions about how to MakeWebMD Great Again“Even thoughWebMD is the top health portal on the web, turning traffic into revenue is hard to do as a lot of websites have found out, ” says Meyer. “There are opportun...
Source: Pharma Marketing Blog - March 3, 2017 Category: Pharmaceuticals Tags: DTC Advertising WebMD Source Type: blogs

Is " Right to Try " a Good Idea?
Last night, President Trump called on the FDA to speed the approval of drugs to treat life-threatening diseases,"deriding the agency ’s current process as'slow and burdensome'," according to thisSTATnews article.One solution to alleviating FDA ’s “slow and burdensome” approval process and getting potentially life-saving drugs to patients is"Right to Try" laws that would allow people with fatal illnesses to gain access to experimental medicines, even though they are not enrolled in a clinical trial. VP Pence and other lawmakers support this approach (seehere).“We sho...
Source: Pharma Marketing Blog - March 1, 2017 Category: Pharmaceuticals Tags: Drug Approval FDA Pence Right to Try Trump Source Type: blogs

To Boost Sales, Gilead's Hep C Awareness Ad Focuses on Baby Boomers
Direct-to-Consumer (DTC) drug ads are less and less effective according to several studies including the eyeforpharma Whitepaper “The Great DTC Shake-Up: Patient perspectives on direct-to-consumer advertising. ”One reason for this is a"negative reaction to the use of what could be perceived as'scare tactics' or shock value to garner attention in a crowded media environment."In that report, I was quoted as saying “scare tactics might be good for awareness.” Now, however, I'm beginning to rethink that, especially whendisease awareness adsare scaring a large portion of the populat...
Source: Pharma Marketing Blog - February 23, 2017 Category: Pharmaceuticals Tags: Gilead Harvoni Hepatitis C HepC Sovaldi Source Type: blogs

Bob Ehrlich of DTC Perspectives Should Do Better Research & Fact Checking Before He Calls Out Media for " Misreporting " on DTC Off-Label Promotion
I just received an email missive from Bob Ehrlich (@BobEhrlich_DTC), Chairman of DTC Perspectives, Inc., with the subject line " Media Misreporting Advertising Off-label Use. "Ehrlich said " I was shocked to see media stories saying DTC may expand to cover off label use. What! This erroneous idea came from an FDA open meeting held 11/16 to discuss off label use based on court cases allowing drug companies the right to discuss them. "WRONG!I first reported that the FDA was interested in hearing comments about off-label drug promotion to " patient and consumer audiences " back in September, 2016...
Source: Pharma Marketing Blog - February 17, 2017 Category: Pharmaceuticals Tags: Bob Ehrlich DTC Advertising FDA off-label promotion Source Type: blogs

Pharma CEOs Speak Out About Drug Prices
Pharmaguy ’s Selected List of Pharma CEOs’ Words of Wisdom Regarding Drug Prices, Jobs, and TaxesCEOs include:PHARMA BRO ’ MARTIN SHKRELIALLERGAN CEO BRENT SAUNDERSPFIZER CEO IAN READMYLAN CEO HEATHER BRESCHMARATHON CEO JEFF ARONINLILLY CEO DAVID RICKSREGENERON CEO LEONARD SCHLEIFERNOVARTIS CEO JOESEPH JIMENEZACORDIA CEO RON COHENPharma CEOs Speak Out About Drug Prices fromPharmaGuy.com (Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - February 17, 2017 Category: Pharmaceuticals Tags: Drug prices Pharma CEOs and Big Wigs Source Type: blogs

Pharma is Spending More on DTC Advertising But Its Effectiveness is Decreasing, Says New Survey
“The DTC Attitudes, Behaviors, and Preferences Survey” conducted by Health Stories Project – Insights (HSPi) and published within the eyeforpharma Whitepaper “The Great DTC Shake-Up: Patient perspectives on direct-to-consumer advertising” in partnership with Health Perspectives Groups shows that as investment in DTC increases its effectiveness is decreasing. Only 22% of patients interviewed liked seeing advertisements for prescription drugs versus 52% in 1999.What is more, says eyeforpharma, Pharma ’s approach to DTC is"decoupling from patient needs causing patients to disengage fro...
Source: Pharma Marketing Blog - February 13, 2017 Category: Pharmaceuticals Tags: DTC Advertising eyeforpharma Source Type: blogs

Who Is the Most “Fantastic” Person Trump Has in Mind to Lead the FDA?
In a recent email,STAT: The Readout asked"Who's the next Mr. (or Ms.) Fantastic?":"President Trump has a'fantastic person' in mind to nominate as his new FDA commish. While we wait for his announcement, we're asking for your vote: Who is most likely to hear'You ’re Hired!?'"5 candidates were put forward. It turns out that NONE is a woman.Balaji Srinivasan, the long shot: This Silicon Valley darling may have expressed just a touch too much derision for the FDA on Twitter.[FromSTATnews] Srinivasan, for his part, has claimed the FDA creates “catastrophes” to increa...
Source: Pharma Marketing Blog - February 6, 2017 Category: Pharmaceuticals Tags: FDA FDA Commissioner Trump Source Type: blogs

DTC Drug Ads Are Effective, But Confusing to Patients Say Physicians
Results from a new"microsurvey" (N = 319) performed byInCrowd, a provider of real-time market intelligence to the life sciences and healthcare firms, reveal"perhaps surprising" U.S. healthcare provider (HCP) perceptions on the efficacy of direct-to-consumer (DTC) ads. Specifically, HCPs say DTC drug ads drove patients to asks three times as many questions today than they did 5 years ago, but 87% observed patient confusion with ads.This sounds impressive, but looking at the data, HCPs say they receive only 6 questions about DTC drug ads per week from patients vs. 2 times per week 5 years ago. It just may...
Source: Pharma Marketing Blog - January 26, 2017 Category: Pharmaceuticals Tags: DTC Advertising InCrowd Source Type: blogs

PhRMA Should Have Listened to THIS " Guy in a Hoodie "
Last year I suggest that the pharmaceutical industry put some distance between it a"Pharma Bro" Martin Shkreli. I said (here):"Frankly, I'm getting tired of it all. Shkreli had his 15 minutes of fame. Let's move on. It's time for the pharma industry to get its 15 minutes of fame by doing something substantial to distance itself from the likes of Shrkreli."But, I added a caveat:"The mainstream drug industry cannot distance itself from'wolves' like Shkreli merely through better corporate communications."Unfortunately, the drug industry (aka The Pharmaceutical Research and Man...
Source: Pharma Marketing Blog - January 25, 2017 Category: Pharmaceuticals Tags: PhRMA Source Type: blogs

Pfizer's New Viagra TV Ad Has a Unique Mobile " Call to Action "
As reported by FiercePharma (here), Pfizer ’s new TV commercial for Viagra, which encourages patients to text a keyword from their mobile phones to receive special discounts, appears to be " a first " for pharma Marketing.I decided to have some fun with a few stills from the ad: (Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - January 19, 2017 Category: Pharmaceuticals Tags: Viagra Source Type: blogs

Does FDA Guidance About Pharma Communications with Payors Open a Path to Off-Label Discussions?
At the November, 2016, FDA public hearing on off-label promotion, representatives of the drug industry made a case for allowing companies to inform payers of off-label uses of their products.Payers “play such a gatekeeping role with respect to patients,” said Kellie Combs, an attorney for Ropes& Gray, who testified at the hearing on behalf of the Medical Information Working Group. “There's a real interest in getting information to payers as soon as possible. ”In addition, certain types of data, like demonstrating a drug's use in subpopulations and sharing pharmacoeconomic data, are examp...
Source: Pharma Marketing Blog - January 18, 2017 Category: Pharmaceuticals Tags: FDA Guidance HCEI off-label promotion Payors Source Type: blogs

Fact Checking Puzzling Criticisms of a " Puzzling " DTC Study Proposed by FDA
I get periodic emails from Bob Ehrlich, Chairman of DTC Perspectives, Inc., giving his opinion on various direct-to-consumer (DTC) advertising issues.Although I often do not agree with Ehrlich on many issues, I value his perspective and often respond to him via this blog (read, for example,"Are We at the Saturation Point Viz-a-Viz Celebrity Pharma Endorsements?"). We've even had a head-to-head podcast debate (listen to"Are Drug Marketers an Endangered Species?").In a recent email missive, Ehrlich calls FDA ’s recently proposed study of deception in DTC ads (read “Another FDA Study: Can H...
Source: Pharma Marketing Blog - January 15, 2017 Category: Pharmaceuticals Tags: Bob Ehrlich DTC Advertising FDA Study Source Type: blogs

Top Pharma Companies on Facebook
Back in August, 2011, Facebook opened up comments on ALL pharma pages, which meant that the pharmaceutical industry no longer was able to shut off comments on their product-related pages. Consequently, several companies decided to shut down their pages (read, for example, "Pharma Facebook Pages Being Phased Out" and "Janssen to Shut Down Psoriasis 360 FaceBook Page" ).These days Facebook offers new opportunities and tools for the pharmaceutical industry to do promotions such as disease awareness campaigns (e.g., "Novartis, Queen Latifah,& American Heart Association Team Up on Facebook Live Broa...
Source: Pharma Marketing Blog - January 12, 2017 Category: Pharmaceuticals Tags: FaceBook Source Type: blogs

FDA Study is Designed to Justify a New BadAd Program for Consumers, IMHO
The FDA plans to do two new studies supposedly to gauge the “ability of consumers and healthcare professionals (HCPs) to independently identify deceptive prescription drug promotion” (see the Federal Register Noticehere).A closer examination of the proposal, however, suggests that the real goal is to promote the Agency's BadAd program and open it up to consumers.TheBad Ad Program is administered by the agency ’s Office of Prescription Drug Promotion (OPDP) in the Center for Drug Evaluation and Research. The program's goal is to help raise awareness among healthcare providers about misleading ...
Source: Pharma Marketing Blog - January 9, 2017 Category: Pharmaceuticals Tags: FDA Study Source Type: blogs

Pharmaguy's Top Five 2017 New Year's Resolutions for the Pharma Industry
As is my tradition – as well as the tradition for many other editors/pundits – it’s time for me to tell pharma what I’d like to see included in its list of 2017 New Year's Resolutions.Last year I noted that 2015 wasn ’t an especially good year considering that “the media and politicians have found a face for evil pharma and rising drug prices: Martin Shkreli!” (here).It ’s déjà vu all over again! Only this time many more evil pharma faces have come forward including the CEO of Mylan, aka “Pharma Sis” (read “Mylan ‘Gamed the System&rsq...
Source: Pharma Marketing Blog - December 29, 2016 Category: Pharmaceuticals Tags: Celebrities Drug prices DTC Advertising FDA New Year ' s Resolution off-label PhRMA Guidelines women Source Type: blogs

FDA's Last Licks for 2016: Issues SIX (6) Enforcement Letters in December, So Far!
Click on image for enlarged view.Just when you thought the FDA was finished issuingWarning andUntitled letters for 2016, it issued 2 more - both Untitled letters - last week, bringing the total issued in December to 6! The grand total to date is 11 letters, including 3 Warning letters.I suspect FDA is responding to critical posts such as the one I wrote on 8 December 2016 citing a total of only 8 letters up until that date. A week later I had to update that (here) when the total reached 9 letters for 2016. I characterized that as a"slight uptick" in enforcement compared to 2015 when FDA also issued 9 total letter...
Source: Pharma Marketing Blog - December 28, 2016 Category: Pharmaceuticals Tags: FDA Regulation waring letters YouTube Source Type: blogs

Images Tell the Story of Pharma in 2016
Yes, 2016 was a lousy year for many people and even for the drug industry, but for different reasons. I've already reviewed data from 2016 that document some good news for pharma (see"Charts& Graphs Tell the Story of Pharma in 2016").Another way to look at 2016 is through images. Some of my favorite images from 2016 are collected in the Slideshare presentation embedded below. Click on"Read more" to access a clickable list of references.Pharma Marketing News 2016 Year in Review: Images fromPharmaGuy.comRead more » (Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - December 27, 2016 Category: Pharmaceuticals Tags: 2016 Source Type: blogs

What's Roche Doing on Pinterest?
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - December 22, 2016 Category: Pharmaceuticals Tags: Pinterest Roche Source Type: blogs

What's Boehringer Ingelheim Doing on Pinterest?
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - December 19, 2016 Category: Pharmaceuticals Tags: Boehringer Ingelheim Pinterest Source Type: blogs

Top Pharma Companies on Pinterest
According to ad agency AbelsonTaylor (AT), Pinterest has"enormous potential for healthcare marketing. Healthcare marketers should be engaging the outstanding attributes of Pinterest in their digital, e-commerce and social media marketing strategies and tactics" (read morehere). AT suggests the following types of content are appropriate for pharma marketing via Pinterest:Disease awareness (for clinicians and patients)History of disease/treatment (for clinicians and patients)Support groups/personal experiences (for consumers and patients)Product launch market preparation measures (for clinicians)Health association,...
Source: Pharma Marketing Blog - December 17, 2016 Category: Pharmaceuticals Tags: Pinterest Source Type: blogs